Node-Negative in Clinical Utility

OncLive presents Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD

HR+ Breast Cancer: Oncotype DX Breast Recurrence Score test and TAILORx

Node-negative cancer

Whether patients have node-negative or node-positive breast cancer, the Breast Recurrence Score test is both prognostic and predictive – providing both important prognostic information about the estimated risk of distant recurrence and the likelihood of adjuvant chemotherapy benefit.1-6

Learn more about the study results:

Prognostic Clinical Trial Results:
Node-Negative NSABP B-14 Study
Predictive Clinical Trial Results:
Node-Negative NSABP B-20 Study
Predictive Clinical Trial Results:
TAILORx

Node-Negative Prognostic Clinical Trial Results

The Recurrence Score result is directly associated with the rate of distant recurrence.1, 4


NSABP B-14 Study

10-year rate of distant recurrence was significantly lower for patients with low Recurrence Score results compared to high results


Low Intermediate High Risk graph
Low Recurrence Score result High Recurrence Score result

Prospective analysis of archived tissue from 668 stage I or II patients with estrogen receptor (ER)-positive, node-negative, invasive breast cancer treated with tamoxifen. Twenty-nine percent of patients were < 50 years of age, and 62% had tumors that were ≤ 2.0 cm in size. The majority of patients (51%) in this study had low Recurrence Score results.1


Node-Negative Predictive Clinical Trial Results

Only the Oncotype DX Breast Recurrence Score test predicts the likelihood of chemotherapy benefit for node-negative patients.2


NSABP B-20 Study: Low Recurrence Score result predicted little to no benefit from chemotherapy

Low Recurrence Score graph Intermediate Recurrence Score graph

NSABP B-20 Study: High Recurrence Score result predicted large benefit from chemotherapy

Prospective analysis of archived tissue from 651 patients with ER-positive, node-negative, invasive breast cancer treated with tamoxifen or tamoxifen plus CMF/MF. Approximately 45% of the patients were < 50 years of age, two-thirds of tumors were ≤ 2.0 cm in size, and 16% of tumors were progesterone receptor-negative.2

High Recurrence Score graph

Node-Negative Predictive Clinical Trial Results


LEARN MORE ABOUT TAILORx


MORE TOPICS:

  • Is your patient eligible
  • Clinical validation trials
  • Interpreting test results
    • REFERENCES

    1. Paik et al. N Engl J Med. 2004.
    2. Paik et al. J Clin Oncol. 2006.
    3. Albain et al. Lancet Oncol. 2010.
    4. Dowsett et al. J Clin Oncol. 2010.
    5. Habel et al. Breast Cancer Res. 2006.
    6. Toi et al. Cancer. 2010.

    a. DOI: 10.1056/NEJMoa1804710.

    *American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy

    Stay in Touch

    Have questions? We're here to help.

     Contact Us
    Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
    In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
    Making cancer care smarter.®
    X

    We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.